Transcriptional Activation of E2F1 Gene Expression by 17beta-estradiol in MCF-7 Cells is Regulated by NF-Y-Sp1/estrogen Receptor Interactions
Overview
Molecular Biology
Affiliations
17beta-Estradiol (E2) stimulated proliferation and DNA synthesis in MCF-7 human breast cancer cells, and this was accompanied by induction of E2F1 mRNA and protein levels. Analysis of the E2F1 gene promoter showed that the -146 to -54 region was required for E2-responsiveness in transient transfection assays, and subsequent deletion/mutation analysis showed that a single upstream GC-rich and two downstream CCAAT-binding sites were required for transactivation by E2. Gel mobility shift assays with multiple oligonucleotides and protein antibodies (for supershifts) showed that the -146 to -54 region of the E2F1 gene promoter bound Sp1 and NF-Y proteins in MCF-7 cells. The estrogen receptor (ER) protein enhanced Sp1 interactions with upstream GC-rich sites, and interactions of ER, Sp1, and ER/Sp1 with downstream DNA bound-NF-Y was investigated by kinetic analysis for protein-DNA binding (on- and off-rates), coimmunoprecipitation, and pulldown assays using wild-type and truncated glutathione S-transferase (GST)-Sp1 chimeric proteins. The results showed that Sp1 protein enhanced the Bmax of NF-Y-DNA binding by more than 5-fold (on-rate); in addition, the Sp1-enhanced NF-Y-DNA complex was further stabilized by coincubation with ER and the rate of dissociation (t1/2) was decreased by approximately 50%. Sp1 antibodies immunoprecipitated [35S]NF-YA after coincubation with unlabeled Sp1 protein. Thus, transcriptional activation of E2F1 gene expression in MCF-7 cells by E2 is regulated by multiprotein ER/Sp1-NF-Y interactions at GC-rich and two CCAAT elements in the proximal region of the E2F1 gene promoter. This represents a unique trans-acting protein complex in which ligand-dependent transactivation by the ER is independent of direct ER interactions with promoter elements.
Young K, Hancock G, Fink E, Zigrossi A, Flowers B, Cooper D Breast Cancer Res. 2025; 27(1):10.
PMID: 39825366 PMC: 11742495. DOI: 10.1186/s13058-024-01945-z.
Tylden E, Delgado A, Lukic M, Moi L, Rasmussen Busund L, Pedersen M Sci Rep. 2024; 14(1):25022.
PMID: 39443510 PMC: 11499649. DOI: 10.1038/s41598-024-75557-0.
Young K, Hancock G, Fink E, Zigrossi A, Flowers B, Cooper D Res Sq. 2024; .
PMID: 38978585 PMC: 11230492. DOI: 10.21203/rs.3.rs-4542467/v1.
Young K, Hancock G, Fink E, Zigrossi A, Flowers B, Cooper D bioRxiv. 2024; .
PMID: 38854123 PMC: 11160638. DOI: 10.1101/2024.05.28.596307.
Timilsina S, Rajamanickam S, Rao A, Subbarayalu P, Nirzhor S, Abdelfattah N Cancer Lett. 2022; 540:215717.
PMID: 35568265 PMC: 10313451. DOI: 10.1016/j.canlet.2022.215717.